Protocol summary

Study aim
Determining the effect of Bane gum on fatty liver
Design
This study will be a three-blind, placebo-controlled, parallel-group, phase 3 clinical trial on 46 patients, and blocking design will be used for randomization.
Settings and conduct
This study will be conducted at the Faculty of Nutritional Sciences and Food Technology of Kermanshah University of Medical Sciences- Iran. Completing the physical activity questionnaires and 3-day food record will be done at the beginning of the study, in the middle of the study and at the end of the study. In addition to the measurement of anthropometric indices, body composition and blood pressure at the beginning and end of the study, 10 cc of venous blood will be taken from all patients fasting for 10-12 hours to perform serum tests and expression of the desired genes.
Participants/Inclusion and exclusion criteria
Inclusion criteria include Grade 1 and 2 fatty liver and non-entry conditions include having gastrointestinal, liver (fibrosis, cirrhosis, HCC), autoimmune, kidney, thyroid and cardiovascular diseases.
Intervention groups
People with grade 1 and 2 fatty liver will be randomly divided into placebo (n=21) and supplement (n=21) groups. Patients in the supplement group were given 2 tablespoons of oral emulsion every 12 hours, each spoon containing 500 mg of Pistacia atlantica gum. Patients in the placebo group will receive 2 tablespoons of oral emulsion with the same appearance as the supplement every 12 hours. Also, people of both groups are subjected to a weight loss diet of 250 kilocalories, reducing the amount of energy needed daily. The duration of the intervention will be 8 weeks.
Main outcome variables
- Oxidative stress indicators (MDA, TAC, TOS) - Gene expression of antioxidant enzymes (NQO1, HMOX-1, GCLC) - Nrf-2 gene expression - Serum levels of inflammatory and anti-inflammatory factors (IL-10, IL-6)

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20231219060466N1
Registration date: 2024-01-05, 1402/10/15
Registration timing: retrospective

Last update: 2024-01-05, 1402/10/15
Update count: 0
Registration date
2024-01-05, 1402/10/15
Registrant information
Name
Roghayeh Mostafaei
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 83 3827 0803
Email address
r_mostafai@yahoo.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2023-12-22, 1402/10/01
Expected recruitment end date
2023-12-31, 1402/10/10
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Investigating the effect of Bane (Pistacia atlantica sub. Kurdica) gum oral supplement on the improvement of oxidant/ antioxidant and inflammatory indices, and Keap1/Nrf-2/ARE signaling pathway in patients with non-alcoholic fatty liver disease: A Randomized Clinical Trial
Public title
Investigating the effect of wild pistachio gum in the treatment of fatty liver disease
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Having fatty liver grade 1 and 2 based on diagnosis by ultrasound Age 18-60 years Body mass index in the range of 25-35 kg/m2
Exclusion criteria:
The presence of secondary causes of hepatic steatosis (such as hepatitis B and C virus, autoimmune hepatitis, hemochromatosis, celiac disease, pituitary hypofunction, hypothyroidism, Wilson's disease, abetalipoproteinemia or corticosteroid drugs) Suffering from diseases such as Autoimmune, digestive, liver diseases (fibrosis, cirrhosis, (HCC, kidney, thyroid and cardiovascular diseases), severe respiratory disease (asthma and chronic bronchitis) Pregnancy Breastfeeding Alcohol consumption, consumption of plant sterols, psyllium and oil Fish, consumption of any kind of vitamins and minerals, nutritional supplements The existence of allergy to all kinds of Pistachio plant species
Age
From 18 years old to 60 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 46
Randomization (investigator's opinion)
Randomized
Randomization description
A random sequence will be generated by using the random block method using a random block of 4 for a total of 12 blocks that will be created using the website https://www.sealedenvelope.com.The person who collects the information is unaware of the type of allocation of the samples to the study groups. The following things will be considered regarding the implementation of the random assignment process: a) One English letter will be assigned to each of the groups: A to the supplement group, B to the placebo group. b) A sequence will be created for a sample size of 46 . c) For the concealment process of random allocation, 46 non-transparent envelopes and 46 cards (the size of the total sample size) will be prepared. Inside each envelope, 4 cards will be placed in the order of the sequence in each block. Block numbers will be written on each envelope. The name of the desired group will be written on each card in sequence. Due to the fact that people do not know about the random sequence and the considered blocks, random allocation concealment is observed and before the allocation of the individual, the allocated group will not be clear.
Blinding (investigator's opinion)
Triple blinded
Blinding description
Except for an individual outside the study group who will number the randomization list and drug containers sequentially, all other investigators and all patients will be blinded to study group assignment. The placebo will be identical in shape and appearance to the supplement and will be distributed in similar containers.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Kermanshah University of Medical Sciences
Street address
Shahid Beheshti Blvd
City
Kermanshah
Province
Kermanshah
Postal code
6714673159
Approval date
2023-12-18, 1402/09/27
Ethics committee reference number
IR.KUMS.REC.1402.442

Health conditions studied

1

Description of health condition studied
Fatty liver
ICD-10 code
K76.0
ICD-10 code description
Fatty (change of) liver, not elsewhere classified

Primary outcomes

1

Description
Oxidative stress indicators (MDA, TAC, TOS)
Timepoint
Before and after study
Method of measurement
Calorimetric method

2

Description
Gene expression of antioxidant enzymes (NQO1, HMOX-1, GCLC)
Timepoint
Before and after study
Method of measurement
Real- Time PCR

3

Description
Nrf-2 gene expression
Timepoint
Before and after study
Method of measurement
Real- Time PCR

4

Description
Serum levels of inflammatory and anti-inflammatory factors (IL-10, IL-6)
Timepoint
Before and after study
Method of measurement
ELIZA method

Secondary outcomes

1

Description
Fasting insulin
Timepoint
Before and after study
Method of measurement
Calorimetric method

2

Description
fasting blood sugar
Timepoint
Before and after study
Method of measurement
Calorimetric method

3

Description
Insulin resistance index (HOMA-IR)
Timepoint
Before and after study
Method of measurement
Formula

4

Description
Insulin sensitivity index (QUICKI)
Timepoint
Before and after study
Method of measurement
Formula

5

Description
Function of pancreatic beta cells (HOMA-β)
Timepoint
Before and after study
Method of measurement
Formula

6

Description
Liver enzymes (AST, ALT)
Timepoint
Before and after study
Method of measurement
Calorimetric method

7

Description
Lipid profile (TC, HDL-C, TG, LDL-c)
Timepoint
Before and after study
Method of measurement
Enzymatic method

8

Description
The degree of hepatic steatosis
Timepoint
Before and after study
Method of measurement
sonography

Intervention groups

1

Description
Intervention group: Patients in the supplement group will take every 12 hours, 2 tablespoons of oral emulsion, each spoon containing 500 mg of Pistacia atlantica Sub Kurdica gum for 2 months. This emulsion will be produced by Barij Essential Pharmaceutical Company.
Category
Treatment - Other

2

Description
Control group: Patients in the placebo group will take 2 tablespoons of oral emulsion every 12 hours with the same appearance and composition as the gum supplement (but without Pistacia atlantica Sub. Kurdica gum) for 2 months. This emulsion will be produced by Barij Essential Pharmaceutical Company.
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Bostan Specialized Medical Clinic
Full name of responsible person
Dr. Mohssen Fatahi Banvandpour
Street address
Sorkhe lizhe
City
Kermanshah
Province
Kermanshah
Postal code
6714673159
Phone
+98 83 3836 0014
Email
src_research@kums.ac.ir

2

Recruitment center
Name of recruitment center
Mehr clinic
Full name of responsible person
Dr. Mohamad Gharib Salehi
Street address
Haj Mohamad Taghi Esfahani
City
Kermanshah
Province
Kerman
Postal code
6714673159
Phone
+98 83 3836 0014
Email
src_research@kums.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Kermanshah University of Medical Sciences
Full name of responsible person
Dr. Siros Jalili
Street address
Shahid Beheshti Blvd
City
Kermanshah
Province
Kermanshah
Postal code
6714673159
Phone
+98 83 3836 0014
Email
src_research@kums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Kermanshah University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Kermanshah University of Medical Sciences
Full name of responsible person
Roghayeh Mostafaei
Position
PhD Student
Latest degree
Master
Other areas of specialty/work
Nutrition
Street address
Dolatabad
City
Kermanshah
Province
Kermanshah
Postal code
671987915
Phone
+98 83 3827 0803
Email
r_mostafai@yahoo.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Kermanshah University of Medical Sciences
Full name of responsible person
Seyed Mostafa Nachvak
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
ِDolatabad
City
Kermanshah
Province
Kermanshah
Postal code
6714673159
Phone
+98 83 3827 2001
Email
smnachvak@hotmail.com

Person responsible for updating data

Contact
Name of organization / entity
Kermanshah University of Medical Sciences
Full name of responsible person
Roghayeh Mostafaei
Position
PhD Student
Latest degree
Master
Other areas of specialty/work
Nutrition
Street address
Dolatabad
City
Kermanshah
Province
Kermanshah
Postal code
671987915
Phone
+98 83 3827 0803
Email
r_mostafai@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Not applicable
Title and more details about the data/document
All information can be shared.
When the data will become available and for how long
6 months after the results are published
To whom data/document is available
Scientific referees of reputable journals
Under which criteria data/document could be used
Checking the accuracy of data by reviewer
From where data/document is obtainable
Email to corresponding author: Dr Seyed Mostafa Nachvak smnachvak@hotmail.com
What processes are involved for a request to access data/document
Email The expected period is one month
Comments
Loading...